TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04443088: An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 78 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT04443088 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04443088 Rescue Dossier →